New Rheumatoid Arthritis Medication to Come Before FDA Advisory Committee
News
The Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) will examine data supporting Amgen biotechnoloy company’s Biologics License Application (BLA) for ABP 501. The compound is a biosimilar candidate to Humira (adalimumab), ... Read more